{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting","groups":[{"description":"A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.","id":"OG000","title":"Autologous-Allogeneic Hematopoietic Stem Cell Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to the significance of the allo-PBSC transplant as a component to the treatment plan, participants who did not receive allo-PBSC are not included.","reportingStatus":"POSTED","timeFrame":"2 years after the last participant is enrolled.","title":"Incidence of Graft Versus Host Disease (GvHD)","type":"PRIMARY","unitOfMeasure":"Participants"}